期刊
BONE MARROW TRANSPLANTATION
卷 54, 期 -, 页码 721-726出版社
NATURE PUBLISHING GROUP
DOI: 10.1038/s41409-019-0596-z
关键词
-
资金
- Gilead Sciences Europe Ltd
- Cell Source, Inc.
- Chorafas Institute for Scientific Exchange of the Weizmann Institute of Science
- Kiadis Pharma
- Miltenyi Biotec
- Celgene
- Centro Servizi Congressuali
- Almog Diagnostic
One of the remaining and unresolved problems in allogeneic stem cell transplantation, especially following a T cell-depleted transplant as often performed in the setting of haploidentical transplantation, is the relapse of the underlying hematological malignancy. It has been demonstrated that in the last years we have made major progress in controlling infections, acute and chronic GvHD and making stem cell transplantation available to elderly patients. However, little improvement has been made to achieve better tumor control and to lower the relapse rate. Thus, novel immunotherapeutic strategies are increasingly used prior to or even following allogeneic stem cell transplantation to better control the underlying malignancy and thus, to reduce the relapse rate. These novel immunotherapeutic strategies comprise monoclonal antibodies, immunotoxins and even more effective T cell redirecting strategies like bispecific antibodies and T cells transduced with either chimeric antigen receptors (CAR) or (affinity-tuned) T cell receptors (TCR).
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据